首页|The evolution of cancer genomic medicine in Japan and the role of the National Cancer Center Japan

The evolution of cancer genomic medicine in Japan and the role of the National Cancer Center Japan

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
The journey to implement cancer genomic medicine(CGM)in oncology practice began in the 1980s,which is considered the dawn of genetic and genomic cancer research.At the time,a variety of activating oncogenic alterations and their functional significance were unveiled in cancer cells,which led to the development of molecular targeted therapies in the 2000s and beyond.Although CGM is still a relatively new discipline and it is difficult to predict to what extent CGM will benefit the diverse pool of cancer patients,the National Cancer Center(NCC)of Japan has already contributed considerably to CGM advancement for the conquest of cancer.Looking back at these past achievements of the NCC,we predict that the future of CGM will involve the following:1)A biobank of paired cancerous and non-cancerous tissues and cells from various cancer types and stages will be developed.The quantity and quality of these samples will be compatible with omics analyses.All biobank samples will be linked to longitudinal clinical information.2)New technologies,such as whole-genome sequencing and artificial intelligence,will be introduced and new bioresources for functional and pharmacologic analyses(e.g.,a patient-derived xenograft library)will be systematically deployed.3)Fast and bidirectional translational research(bench-to-bedside and bedside-to-bench)performed by basic researchers and clinical investigators,preferably working alongside each other at the same institution,will be implemented;4)Close collaborations between academia,industry,regulatory bodies,and funding agencies will be established.5)There will be an investment in the other branch of CGM,personalized preventive medicine,based on the individual's genetic predisposition to cancer.

Cancer genomic medicinebiobankpatient-derived xenograftmulti-gene panel testwhole genome sequencing

Teruhiko Yoshida、Yasushi Yatabe、Ken Kato、Genichiro Ishii、Akinobu Hamada、Hiroyuki Mano、Kuniko Sunami、Noboru Yamamoto、Takashi Kohno

展开 >

Department of Genetic Medicine and Services,National Cancer Center Hospital,Tokyo 104-0045,Japan

Department of Diagnostic Pathology,National Cancer Center Hospital,Tokyo 104-0045,Japan

Clinical Research Support Office,Clinical Research Coordinating Section,Biobank Translational Research Support Section,National Cancer Center Hospital,Tokyo 104-0045,Japan

Department of Pathology and Clinical Laboratories,National Cancer Center Hospital East,Chiba 277-8577,Japan

Division of Molecular Pharmacology,National Cancer Center Research Institute,Tokyo 104-0045,Japan

National Cancer Center Research Institute,Tokyo 104-0045,Japan

Department of Laboratory Medicine,National Cancer Center Hospital,Tokyo 104-0045,Japan

Department of Experimental Therapeutics,National Cancer Center Hospital,Tokyo 104-0045,Japan

Division of Genome Biology,National Cancer Center Research Institute,Tokyo 104-0045,Japan

展开 >

2024

10.20892/j.issn.2095-3941.2023.0036

癌症生物学与医学(英文版)
中国抗癌协会

癌症生物学与医学(英文版)

CSTPCD
影响因子：1.07
ISSN：2095-3941
年,卷(期)：2024.21(1)
  • 75